http://www.greenmedinfo.com/blog/how-vaccinated-kids-infect-non-vaccinated
How Vaccinated Kids Infect The Non-Vaccinated
Posted on:
Sunday, February 8th 2015 at 3:45 pm
Written By:
Sayer Ji,
Founder
With the thousands of mainstream media articles blaming the
non-vaccinated for disease outbreaks, this article will provide a
necessary counterbalance by showing the vaccinated can (and do) infect
the non-vaccinated...
A groundbreaking study published in 2013 in the journal
Vaccine titled,
"Comparison of
virus shedding after lived attenuated and pentavalent reassortant
rotavirus vaccine," referenced the fact that rotavirus
vaccines contain live viruses capable of causing infection, shedding
and even transmission to non-vaccinated subjects:
- "In fact, transmission of these two rotavirus vaccines or
vaccine-reassortment strains to unvaccinated contacts has been detected
[9–13][1]
, even in the absence of
symptoms."
One of the five studies referenced in the passage above confirming
that the vaccinated can infect the non-vaccinated,
"Sibling
transmission of vaccine-derived rotavirus (RotaTeq) associated with
rotavirus gastroenteritis," published in 2009, is the first
report in the literature to identify the transmission of rotavirus
vaccine-derived virus to unvaccinated contacts resulting in symptomatic
rotavirus gastroenteritis requiring emergency medical attention:
- "We document here the occurrence of vaccine-derived rotavirus
(RotaTeq [Merck and Co, Whitehouse Station, NJ]) transmission from a
vaccinated infant to an older, unvaccinated sibling, resulting in
symptomatic rotavirus gastroenteritis that required emergency department
care."
The study also indicated that two of the five strains of rotavirus
within the Rotateq reassorted to produce a more harmful virus either
within the vaccinated infant or within the subsequently infected
unvaccinated sibling:
- "Results of our investigation suggest that reassortment between
vaccine component strains of genotypes P7[5]G1 and P1A[8]G6 occurred
during replication either in the vaccinated infant or in the older
sibling, raising the possibility that this reassortment may have
increased the virulence of the vaccine-derived virus."
This phenomenon of Rotateq vaccine strain reassortment and
subsequent gastoenteritis infection in vaccine recipients was also
observed in a 2012 study in 61 infants.[2]
Additionally, A Nicaraguan study published in 2012 found "the
widespread use of the RotaTeq vaccine has led to the introduction of
vaccine genes into circulating human RVs.," revealing that the
widespread introduction of the vaccine strain has altered the genetic
makeup of wild-type rotavirus that now infects exposed
populations.[3]
It has been estimated that between 80-100% of infants shed rotavirus at
some point during 25-28 days after vaccination.[4]
[5] This reveals that the vaccinated, contrary to
widespread assumptions about the the risks represented by the
non-vaccinated, pose a clear risk of infecting the non-vaccinated, and
may be producing the ideal virological conditions for the recombination
of diverse rotavirus strains into vaccine-resistant 'super
viruses.'
Another case study, reported on in the
National Vaccine Information Center's document on vaccine viral
shedding:
- "In 2010, a case report was published in Pediatrics
describing a 30-month old healthy boy who had never received rotavirus
vaccine and was infected with vaccine strain rotavirus. 237 He ended up
in the emergency room with severe gastroenteritis 10 days after his
healthy two-month old brother was given a dose of Merck's RotaTeq
vaccine. A stool sample was taken in the emergency room and came back
positive for RotaTeq vaccine derived strains after RT-PCR
testing."
The authors of the case report noted that "transmission of
RotaTeq strains to unvaccinated contacts was not evaluated in the pivotal
[pre-licensure] clinical trials." They added that both RotaTeq
and Rotarix [GlaxoSmithKline Biologicals] vaccines have "the
potential for vaccine-virus transmission to contacts."
The Rotateq Vaccine: Shot Through with Conflict of
Interest
The Rotateq rotavirus vaccine was co-created by Dr. Paul
Offit, widely recognized as the vaccine industry's leading promoter and
apologist. He is the co-patent holder of one of two live rotavirus
vaccines the FDA has approved, and which the
CDC recommends should be administered to infants in 3 doses at ages 2
months, 4 months, and 6 months.
Historically incapable of self-recusal, despite his glaring conflicts of
interest, Offit regularly positions himself as an expert on vaccines,
even though he personally gains from presenting his product (and the
CDC's vaccine schedule as a whole) as safe and effective. Case in
point, in one notorious interview in Parenting magazine he claimed a
child can receive
10,000 vaccines
simultaneously without harm (corrected from 100,000 which he
suggested in a previous interview).
The Rotavirus Vaccine Was Dirty from the Start
The first rotavirus vaccine -- Rotashield -- comprised of four
reassorted rhesus-human rotaviruses was approved in 1999, only to be
withdrawn from the market by the FDA
nine months
later when it was found to increase the risk for a deadly form of
bowel obstruction known as intussusception in a small subset of highly
vulnerable children.[6]
Offit's Rotateq, which consists of 5 reassorted human-bovine retroviruses
(yes, that means GMO), was believed to be a safer alternative when it was
approved by the FDA in 2006, but newly published research reveals his
vaccine suffers from the same exact deadly problems.
Published this month in Vaccine and titled,
"
Intussusception risk after RotaTeq vaccination: Evaluation from worldwide
spontaneous reporting data using a self-controlled case series
approach", the study evaluated worldwide reports to the
manufacturer of Rotateq up to May 2014, adjusting for the phenomenon of
under-reporting. The study found that the relative risk of
intussception associated with the administration of Rotateq vaccine
increases "3-7 days following vaccination, mainly after the first
dose and marginally after the second and third doses." The
increase in relative risk reached 3.45 fold in the period 3-to-7 days
after the first dose, relative to the 15-30-day period control
period.
Another study linking Rotateq to intussusception was published last year
in the New England Journal of Medicine finding approximately 1.5 (95%
CI, 0.2 to 3.2) excess cases of intussusception per 100,000 recipients of
the first dose.[7]
Live Vaccines: A Pandora's Box of Adventitious Viruses
Death or debilitation by bowel obstruction rapidly following Rotateq
vaccination is an acute adverse effect that is unlikely to be overlooked
or ignored. This is why the Vaccine Adverse Effects Reporting System
(VAERS): a passive, vaccine post-marketing surveillance system, has found
it to be a significant side effect. VAERS, however, is believed to
capture as little as less than 1% of the actual damage being done by
vaccines, indicating that the extent of harm of the Rotateq is several
orders of magnitude than presently indicated by this report.
Exposure to Rotateq therefore suffers – like many live vaccines – f“ from
a darker side, as far as adverse effects go, which may take months,
years, or decades to manifest as part of the multifactorial smog cloud of
modern day toxicities and exposures that eventually make their way into
the bottleneck of a classical diagnosis.
Rotateq, for instance, has been identified to be contaminated with a
number of adventitious viruses; that is to say, viruses that contaminated
the live cells and/or biological components involved in the original
vaccine manufacturing process. These surreptitious agents, unknown to the
manufacturers and regulatory agencies that approved them, infected the
vaccines the children given them. These viruses include:
- Porcine
Circovirus 1 (PCV-1): In 2010 the
FDA suspended the Rotarix vaccine due to the discovery that it
was contaminated with PCV-1 virus, a pig virus, the implications of which
as far as human exposure are still unknown. Considered less a risk than
PCV-2, known to cause a debilitating wasting disease in piglets, the FDA
determined, after review, that PCV-1 does not represent a risk to the
millions of children exposed to it.
- Porcine
Circovirus 2 (PCV-2): A 2014 study conducted by CDC researchers
and published in Human Vaccines & Immunotherapeutcs titled,
"Detection of PCV-2 DNA in stool samples from infants vaccinated
with RotaTeq®," found for the first time that PCV-2 is shed in the
stool of those vaccinated with Rotateq. They found "A total of 235
(28.5%) samples from 59 vaccine recipients were positive for PCV-2 DNA by
one or more assays used in this study." Additionally,
"Twenty-two of the 102 vaccine recipients (21.6%) shed RotaTeq®
vaccine strain and 10 of these vaccinees (9.8%) were shedding both PCV
DNA and rotavirus vaccine RNA." In pigs, PCV-2 has been linked
to serious health problems including, "PCV2-associated pneumonia,
PCV2-associated enteritis, PCV2-associated reproductive failure, and
Porcine Dermatitis and Nephropathy Syndrome (PDNS)."
[source].
In 2010, The FDA ruled, against the precautionary principle, that
neither "PCV1 or PCV2 are known to infect or cause illness in
humans, however PCV2 may cause illness in pigs."
-
Baboon endogenous strain 7 retrovirus DNA: a 2014 study published
in Advances in Virology titled, "Screening of Viral Pathogens
from Pediatric Ileal Tissue Samples after Vaccination," found
evidence of contamination with a baboon retrovirus.
-
Class D Simian Retovirus: a 2010 study published in Journal of
Virology revealed that the Rotateq vaccine contains simian
retrovirus DNA (with a 96% match of certainty), which Judy Mikovits, PhD,
confirms may contribute to adverse health effects, regardless of whether
it is a self-replicating virus or not.
Because live vaccines are manufactured through co-culturing cells
and biological fluids from various different species, there is plenty of
opportunity for viruses to adapt to, and recombine to produce
infectious agents capable of far greater virulence. Rotateq is just one
of many vaccines in the CDC's immunization schedule that contain live
viruses capable of infecting those given it, including retroviruses,
which have been called a modern-day Plague owing to the fact that they
are capable of infecting the host as non-HIV acquire immunodeficiency
viruses. For more information read
Dr. Judy Mikovits and Kent Heckenlively's new book Plague or
listen to this
interview of Dr. Mikovits on Fearless Parent Radio.
Clearly, given the evidence revealing the potential unintended, adverse
effects of the Rotateq vaccine, especially the potential for it to infect
those exposed to it with adventitious viruses, the implementation of the
precautionary principle requires the immediate suspension of its use
until proper toxicological reevaluations can be made. Anyone who
questions the safety of the present CDC immunization schedule should be
able to point to the Rotateq as a perfect example of why the schedule is
not at all evidence based but rather founded in a mythological belief in
the safety and effectiveness of products that have never been proven
sound.
REFERENCES
[1] [9] Phua
KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, et al. Evaluation of
RIX4414, a live, attenuated rotavirus vaccine, in a randomized,
double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean
infants. J Infect Dis 2005;192(Suppl. 1):S6–16.
[10] Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC,
Fischer Jr FH, et al. Comparative evaluation of safety and immunogenicity
of two dosages of an oral live attenuated human rotavirus vaccine.
Pediatr Infect Dis J 2005;24:481–8.
[11] Payne DC, Edwards KM, Bowen MD, Keckley E, Peters J, Esona MD,
et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq)
associated with rotavirus gastroenteritis. Pediatrics
2010;125:e438–41.
[12] Boom JA, Sahni LC, Payne DC, Gautam R, Lyde F,
Mijatovic-Rustempasic S, et al. Symptomatic infection and detection of
vaccine and vaccine-reassortant rotavirus strains in 5 children: a case
series. J Infect Dis 2012;206:1275–9.
[13] RRiveraL,Pen
̃aLM,StainierI,GillardP,CheuvartB,SmolenovI,etal.Horizontal transmission
of a human rotavirus vaccine strain—a randomized, placebo- controllled
study in twins. Vaccine 2011;29:9508–13.
[2]
J Infect Dis.
2012 Aug 1;206(3):377-83. doi: 10.1093/infdis/jis361. Epub 2012 May
21.
Identification of strains of RotaTeq rotavirus vaccine in infants with
gastroenteritis following routine vaccination.
Donato
CM1,
Ch'ng LS,
Boniface KF,
Crawford NW,
Buttery JP,
Lyon M,
Bishop RF,
Kirkwood CD.
[3]
Infect Genet
Evol. 2012 Aug;12(6):1282-94. doi: 10.1016/j.meegid.2012.03.007. Epub
2012 Apr 2.
Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with
gastroenteritis in Nicaragua.
Bucardo
F1,
Rippinger CM,
Svensson L,
Patton JT.
[4] Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han
HH, et al. Evaluation of
RIX4414, a live, attenuated rotavirus vaccine, in a randomized,
double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean
infants. J Infect Dis 2005;192(Suppl. 1):S6–16.
[5] Comparison of virus shedding after lived
attenuated and pentavalent reassortant rotavirus vaccine
[6] Centers for Disease Control and Prevention.
Intussusception among recipients of rotavirus vaccine—United States,
11998–1999. JAMA 1999;282:520-1
CrossRef
Medline
Web
of Science
[7]
N Engl J Med.
2014 Feb 6;370(6):503-12. doi: 10.1056/NEJMoa1303164. Epub 2014 Jan 14
Intussusception risk after rotavirus vaccination in U.S. infants.
Yih
WK1,
Lieu TA,
Kulldorff M,
Martin D,
McMahill-Walraven CN,
Platt R,
Selvam N,
Selvan M,
Lee GM,
Nguyen M
